Rebecca Taub - 22 Feb 2022 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role: Chief Medical Officer, President, R&D ** As attorney-in-fact for Reporting Person, Director
Signature: /s/ Brian J. Lynch **
Issuer symbol: MDGL
Transactions as of: 22 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 24 Feb 2022, 19:12:56 UTC
Next filing: 01 Aug 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MDGL	Stock Option (Right to Buy)	Award	$0	+61,500		$0.000000	61,500	22 Feb 2022	Common Stock	61,500	$87.09	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

Remarks:

Chief Medical Officer, President, R&D ** As attorney-in-fact for Reporting Person